ArticleAntimicrobial agents and chemotherapy2011
Identification and characterization of the anti-methicillin-resistant Staphylococcus aureus WAP-8294A2 biosynthetic gene cluster from Lysobacter enzymogenes OH11.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 97 citations in OpenAlex.
- Hfq modulates system-wide regulatory networks controlling biocontrol property inSynthetic and systems biotechnology · 2026Article
- Cooperative Interactions Between Bacillus and Lysobacter Enhance Consortium Stability and Fusarium Wilt Suppression in Cucumber.Microbial ecology · 2025Article
- Two-step localization driven by peptidoglycan hydrolase in interbacterial predation.The ISME journal · 2025Article
- The 'microbiome counterattack': Insights on the soil and root-associated microbiome in diverse chickpea and lentil genotypes after an erratic rainfall event.Environmental microbiology reports · 2023Article
- Article
- Genetic Basis and Expression Pattern Indicate the Biocontrol Potential and Soil Adaption ofMicroorganisms · 2023Article
- Loss of Flagella-Related Genes Enables a Nonflagellated, Fungal-Predating Bacterium To Strengthen the Synthesis of an Antifungal Weapon.Microbiology spectrum · 2023Article
- Nanomedicine: New Frontiers in Fighting Microbial Infections.Nanomaterials (Basel, Switzerland) · 2023Review
- Assembly of an active microbial consortium by engineering compatible combinations containing foreign and native biocontrol bacteria of kiwifruit.Computational and structural biotechnology journal · 2023Article
- Bioactive Lipodepsipeptides Produced by Bacteria and Fungi.International journal of molecular sciences · 2022Review
- Novel indole-mediated potassium ion import system confers a survival advantage to the Xanthomonadaceae family.The ISME journal · 2022Article
- Identification of structurally diverse menaquinone-binding antibiotics with in vivo activity against multidrug-resistant pathogens.Nature microbiology · 2022Article
- Underexplored bacteria as reservoirs of novel antimicrobial lipopeptides.Frontiers in chemistry · 2022Review
- Spectinomycin resistance inFrontiers in microbiology · 2022Article
- Comparative genomics provides insights into the potential biocontrol mechanism of twoFrontiers in microbiology · 2022Article
- Anti-leishmanial compounds from microbial metabolites: a promising source.Applied microbiology and biotechnology · 2021Review
- Lytic potential of Lysobacter capsici VKM B-2533Scientific reports · 2020Article
- Nanomedicine Fight against Antibacterial Resistance: An Overview of the Recent Pharmaceutical Innovations.Pharmaceutics · 2020Review
- Interspecies and Intraspecies Signals Synergistically Regulate Lysobacter enzymogenes Twitching Motility.Applied and environmental microbiology · 2019Article
- Systematic optimization for production of the anti-MRSA antibiotics WAP-8294A in an engineered strain of Lysobacter enzymogenes.Microbial biotechnology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Lysobactor enzymogenes strain OH11 is an emerging biological control agent of fungal and bacterial diseases. We recently completed its genome sequence and found it contains a large number of gene clusters putatively responsible for the biosynthesis of nonribosomal peptides and polyketides, including the previously identified antifungal dihydromaltophilin (HSAF). One of the gene clusters contains two huge open reading frames, together encoding 12 modules of nonribosomal peptide synthetases (NRPS). Gene disruption of one of the NRPS led to the disappearance of a metabolite produced in the wild type and the elimination of its antibacterial activity. The metabolite and antibacterial activity were also affected by the disruption of some of the flanking genes. We subsequently isolated this metabolite and subjected it to spectroscopic analysis. The mass spectrometry and nuclear magnetic resonance data showed that its chemical structure is identical to WAP-8294A2, a cyclic lipodepsipeptide with potent anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and currently in phase I/II clinical trials. The WAP-8294A2 biosynthetic genes had not been described previously. So far, the Gram-positive Streptomyces have been the primary source of anti-infectives. Lysobacter are Gram-negative soil/water bacteria that are genetically amendable and have not been well exploited. The WAP-8294A2 synthetase represents one of the largest NRPS complexes, consisting of 45 functional domains. The identification of these genes sets the foundation for the study of the WAP-8294A2 biosynthetic mechanism and opens the door for producing new anti-MRSA antibiotics through biosynthetic engineering in this new source of Lysobacter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.